Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Product Development

Preclinical data suggest Oxford vaccine could reduce COVID-19 symptoms, won’t provide herd immunity

May 18, 2020 4:05 AM UTC
Updated on May 18, 2020 at 12:26 PM UTC

Preclinical data from a leading COVID-19 vaccine candidate from Oxford University suggest that it may be more like the flu vaccine than the smallpox jab, reducing the severity of symptoms but not preventing infection.

Such a vaccine could help individuals infected with SARS-CoV-2 avoid pneumonia and the downward spiral that all too frequently leads to a ventilator. It would save lives, especially among the most vulnerable, such as the elderly and people with diabetes and other health conditions that put them at high risk of succumbing to COVID-19. ...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article